Pasithea Therapeutics Corp Stock Analysis

KTTA Stock  USD 2.66  0.03  1.14%   
Pasithea Therapeutics Corp is overvalued with Real Value of 2.28 and Target Price of 2.0. The main objective of Pasithea Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Pasithea Therapeutics Corp is worth, separate from its market price. There are two main types of Pasithea Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Pasithea Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Pasithea Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Pasithea Stock Analysis Notes

About 23.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.2. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pasithea Therapeutics recorded a loss per share of 14.79. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 2nd of January 2024. Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida. Pasithea Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. To find out more about Pasithea Therapeutics Corp contact Tiago Marques at 702 514 4174 or learn more at https://www.pasithea.com.

Pasithea Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Pasithea Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Pasithea Therapeutics Corp or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Pasithea Therapeutics generated a negative expected return over the last 90 days
Pasithea Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 486.56 K. Net Loss for the year was (15.51 M) with loss before overhead, payroll, taxes, and interest of (2.21 K).
Pasithea Therapeutics Corp currently holds about 47.94 M in cash with (13.43 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8.
Roughly 23.0% of the company outstanding shares are owned by corporate insiders
Latest headline from news.google.com: KTTA stock touches 52-week low at 2.72 amid market challenges - Investing.com

Pasithea Therapeutics Upcoming and Recent Events

Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pasithea Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
12th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

Pasithea Largest EPS Surprises

Earnings surprises can significantly impact Pasithea Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-08-11
2023-06-30-0.17-0.1440.02615 
2022-11-14
2022-09-30-0.14-0.17-0.0321 
2023-12-29
2023-09-30-0.18-0.14360.036420 
View All Earnings Estimates

Pasithea Therapeutics Environmental, Social, and Governance (ESG) Scores

Pasithea Therapeutics' ESG score is a quantitative measure that evaluates Pasithea Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Pasithea Therapeutics' operations that may have significant financial implications and affect Pasithea Therapeutics' stock price as well as guide investors towards more socially responsible investments.

Pasithea Stock Institutional Investors

Shares
Ubs Group Ag2024-09-30
6.6 K
Morgan Stanley - Brokerage Accounts2024-09-30
1.5 K
Tower Research Capital Llc2024-09-30
601
Royal Bank Of Canada2024-09-30
250
Jpmorgan Chase & Co2024-09-30
150
Bank Of America Corp2024-09-30
18.0
Adar1 Capital Management Llc2024-09-30
0.0
Wells Fargo & Co2024-06-30
0.0
Fmr Inc2024-09-30
0.0
Note, although Pasithea Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Pasithea Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.33 M.

Pasithea Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.94)(0.90)
Return On Capital Employed(0.68)(0.71)
Return On Assets(0.61)(0.64)
Return On Equity(0.68)(0.65)

Management Efficiency

Pasithea Therapeutics has return on total asset (ROA) of (0.379) % which means that it has lost $0.379 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6325) %, meaning that it created substantial loss on money invested by shareholders. Pasithea Therapeutics' management efficiency ratios could be used to measure how well Pasithea Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.9. In addition to that, Return On Capital Employed is expected to decline to -0.71. At present, Pasithea Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 62.1 M, whereas Non Current Assets Total are forecasted to decline to about 5.7 M.
Last ReportedProjected for Next Year
Book Value Per Share 18.54  19.45 
Tangible Book Value Per Share 11.25  16.43 
Enterprise Value Over EBITDA 0.45  0.43 
Price Book Value Ratio 0.40  0.38 
Enterprise Value Multiple 0.45  0.43 
Price Fair Value 0.40  0.38 
Enterprise Value-18.4 M-17.5 M
Understanding the operational decisions made by Pasithea Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta
0.821
Return On Assets
(0.38)
Return On Equity
(0.63)

Technical Drivers

As of the 23rd of December, Pasithea Therapeutics holds the Coefficient Of Variation of (1,278), risk adjusted performance of (0.05), and Variance of 65.43. Pasithea Therapeutics technical analysis gives you tools to exploit past prices in attempt to determine a pattern that determines the direction of the company's future prices.

Pasithea Therapeutics Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Pasithea Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Pasithea Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Pasithea Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pasithea Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pasithea Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pasithea Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Pasithea Therapeutics Outstanding Bonds

Pasithea Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pasithea Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pasithea bonds can be classified according to their maturity, which is the date when Pasithea Therapeutics Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Pasithea Therapeutics Predictive Daily Indicators

Pasithea Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pasithea Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Pasithea Therapeutics Corporate Filings

8K
26th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
14th of November 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
10Q
13th of November 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
11th of October 2024
Other Reports
ViewVerify
7th of October 2024
Other Reports
ViewVerify
8K
30th of September 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
26th of September 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
10Q
13th of August 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify

Pasithea Therapeutics Forecast Models

Pasithea Therapeutics' time-series forecasting models are one of many Pasithea Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pasithea Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Pasithea Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Pasithea Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Pasithea shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Pasithea Therapeutics. By using and applying Pasithea Stock analysis, traders can create a robust methodology for identifying Pasithea entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(25.78)(27.07)
Operating Profit Margin(27.41)(28.78)
Net Loss(24.15)(25.36)
Gross Profit Margin 0.69  0.73 

Current Pasithea Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Pasithea analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Pasithea analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
2.0Strong Buy1Odds
Pasithea Therapeutics Corp current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Pasithea analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Pasithea stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Pasithea Therapeutics, talking to its executives and customers, or listening to Pasithea conference calls.
Pasithea Analyst Advice Details

Pasithea Stock Analysis Indicators

Pasithea Therapeutics Corp stock analysis indicators help investors evaluate how Pasithea Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Pasithea Therapeutics shares will generate the highest return on investment. By understating and applying Pasithea Therapeutics stock analysis, traders can identify Pasithea Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow33.1 M
Common Stock Shares Outstanding1.2 M
Total Stockholder Equity23.4 M
Property Plant And Equipment Net220.5 K
Cash And Short Term Investments16.3 M
Cash16.3 M
Accounts Payable2.6 M
Net Debt-16.2 M
50 Day M A3.3947
Total Current Liabilities2.6 M
Other Operating Expenses16 M
Non Current Assets Total9.4 M
Non Currrent Assets Other-9.2 B
Stock Based Compensation592.27

Complementary Tools for Pasithea Stock analysis

When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges